Is NCT06312137 recruiting?

Yes, NCT06312137 is currently recruiting. This lung cancer study is enrolling participants at 47 locations.

What is the status of NCT06312137?

NCT06312137 is currently recruiting. This is a Clinical Trial trial for lung cancer sponsored by Merck Sharp & Dohme LLC. Status verified Feb 20, 2026 via ClinicalTrials.gov.

Who is eligible for NCT06312137?

This lung cancer trial is targeting 780 participants. Detailed eligibility criteria including age requirements and medical history are listed on this page.

Who can participate in this Lung Cancer study?

Eligibility varies by study, but generally includes adults diagnosed with Lung Cancer who meet specific medical criteria. Complete the interest form above to learn if you may qualify.

Is the study available in Little Rock, Arkansas?

Yes! This study has active research sites in Little Rock, Springdale, Beverly Hills. When you express interest, you'll be connected with the site nearest to you.

What are the benefits of joining a clinical trial for Lung Cancer?

Participants often receive: access to new treatments before they're widely available, close monitoring by medical professionals, study-related care at no cost, and the opportunity to contribute to medical research.

⚡Your ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

NCT06312137 RECRUITINGIRB Ready

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Q: Where is NCT06312137 enrolling participants?

NCT06312137 has 47 active sites including Little Rock, Arkansas; Springdale, Arkansas; Beverly Hills, California and 44 more locations.

(TroFuse-019)

Express Your Interest Today

Interested in learning more? Complete the form below.

First Name *

Last Name *

Email Address *

Phone Number *

ZIP Code *

Age Range *

Preferred Location

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

No-Cost Study Care
Advance Medical Science
Contribute to groundbreaking research
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel (varies by study)
Help Others
Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

1Submit this form
2Phone screening
3In-person assessment if eligible
4Begin participation

About This Study

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).

Who Can Participate

Exclusion Criteria

include but are not limited to the following: Inclusion Criteria:

Has histological or cytological confirmation of squamous or nonsquamous non-small cell lung cancer (NSCLC), resectable clinical Stage II, IIIA or IIIB (with nodal involvement \[N2\]) per AJCC eighth edition guidelines

Has confirmation that either epidermal growth factor receptor (EGFR)-directed or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated as primary therapy

Is able to undergo surgery based on opinion of investigator after consultation with surgeon

Is able to receive neoadjuvant pembrolizumab and platinum-based doublet chemotherapy

Applies to screening for the adjuvant period only, before randomization: Has not achieved pathological complete response (pCR) at surgery by local review of pathology.

Applies to screening for the adjuvant period only, before randomization: Tumor tissue sample from surgical resection has been provided for determinat

❓ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

📋

Study Type

INTERVENTIONAL

👥

Target Enrollment

780 participants

⚧

Gender

ALL

🏢

Sponsor

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

🔒 Secure · 🏥 Expert Care

Find More Lung Cancer Trials by City

Browse all lung cancer clinical trials in these cities — not just this study.

Little Rock, Arkansas Springdale, Arkansas Beverly Hills, California Los Angeles, California San Francisco, California Stamford, Connecticut

Browse More Trials by Condition

Lung Cancer Trials Small Cell Lung Cancer Trials Non-Small Cell Lung Cancer Trials All Conditions →

Looking for Lung Cancer Treatment in Little Rock?

Join others in Arkansas exploring innovative treatment options through clinical research

Lung Cancer Treatment Options in Little Rock, Arkansas

If you're searching for Lung Cancer treatment in Little Rock, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Little Rock, Springdale, Beverly Hills and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Lung Cancer. All study-related care is provided at no cost to participants.

Local Sites

3 locations in Arkansas

Now Enrolling

Up to 780 participants

Quick Start

Screening available now

Why Consider a Clinical Trial for Lung Cancer?

Potential Benefits

✓Access to new treatment approaches before public availability
✓Close monitoring by experienced medical professionals
✓Study-related care provided at no cost
✓Contribute to medical research for Lung Cancer

What to Expect

→Initial screening to determine eligibility
→Regular check-ups and monitoring visits
→Possible compensation for time and travel
→You can withdraw at any time

Frequently Asked Questions About This Lung Cancer Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06312137. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.